Potential impact of ABCB1 (p-glycoprotein) polymorphisms on avermectin toxicity in humans

Archives of Toxicology

Volumn 81, Issue 8, 2007, Pages 553-563

  Macdonald, Neil ^a   Gledhill, Alex ^a  

^a JEALOTT S HILL INTERNATIONAL RESEARCH CENTRE   (United Kingdom)

Author keywords

Avermectin; Haplotype; p Glycoprotein; Pesticide; Polymorphism

Indexed keywords

AVERMECTIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN FUNCTION; ETHNICITY; GENE FREQUENCY; GENE MUTATION; GENE REARRANGEMENT; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HUMAN; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; HAPLOTYPES; HUMANS; IVERMECTIN; P-GLYCOPROTEIN; PESTICIDES; POLYMORPHISM, GENETIC;

CANIS FAMILIARIS; MAMMALIA;

EID: 34447548572     PISSN: 03405761     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00204-007-0193-6     Document Type: Article

References (70)

1. Aarnoudse AL, van Schaik RH, Dieleman J, Molokhia M, van Riemsdijk MM, Ligthelm RJ, Overbosch D, van der Heiden IP, Stricker BH (2006) MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clin Pharmacol Ther 80:367-374
2. Allabi AC, Horsmans Y, Issaoui B, Gala JL (2005) Single nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype profile in a West Black African population. Eur J Clin Pharmacol 61:97-102
3. Bain LJ, LeBlanc GA (1996) Interaction of structurally diverse pesticides with the human mdr1 gene product P-glycoprotein. Toxicol Appl Pharmacol 141:288-298
4. Bauer B, Hartz Am, Fricker G, Miller Ds (2004) Pregnane X receptor upregulation of P-glycoprotein expression and. Mol Pharmacol 66:413-419
5. Borst P, Elferink RO (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537-592
6. Brunner M, Langer O, Sunder-Plassmann R, Dobrozemsky G, Muller U, Wadsak W, Krcal A, Karch R, Mannhalter C, Dudczak R, Kletter K, Steiner I, Baumgartner C, Muller M (2005) Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin Pharmacol Ther 78:182-190
7. Ceckova-Novotna M, Pavek P, Staud F (2006) P-glycoprotein in the placenta: expression, localization, regulation and function. Reprod Toxicol 22(3):400-410
8. Chowbay B, Li H, David M, Cheung YB, Lee EJ (2005) Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 60:159-171
9. Chung K, Yang CC, Wu ML, Deng JF, Tsai WJ (1999) Agricultural avermectins: an uncommon but potentially fatal cause of pesticide poisoning. Ann Emerg Med 34:51-57
10. Crivori P, Reinach B, Pezzetta D, Poggesi I (2006) Computational models for identifying potential P-glycoprotein substrates and inhibitors. Mol Pharm 3:33-44
11. Frelet A, Klein M (2006) Insight in eukaryotic ABC transporter function by mutation analysis. FEBS Lett 580:1064-1084
12. Geary TG (2005) Ivermectin 20 years on: maturation of a wonder drug. Trends Parasitol 21:530-532
13. Hitzl M, Schaeffeler E, Hocher B, Slowinski T, Halle H, Eichelbaum M, Kaufmann P, Fritz P, Fromm MF, Schwab M (2004) Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics 14:309-318
14. Ho GT, Soranzo N, Nimmo ER, Tenesa A, Goldstein DB, Satsangi J (2006) ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. Hum Mol Genet 15:797-805
15. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478
16. Huang J, Casida JE (1997) Avermectin B1a binds to high- and low-affinity sites with dual effects on the gamma-aminobutyric acid-gated chloride channel of cultured cerebellar granule neurons. J Pharmacol Exp Ther 281:261-266
17. Ishikawa T, Onishi Y, Hirano H, Oosumi K, Nagakura M, Tarui S (2004) Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1). Biol Pharm Bull 27:939-948
18. Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162
19. Kerb R (2006) Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 234:4-33
20. Kim RB (2002) Transporters and xenobiotic disposition. Toxicology 181-182:291-297
21. Kim DW, Kim M, Lee SK, Kang R, Lee SY (2006) Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrugresistant epilepsy. Seizure 15:344-347
22. Kimchi-Sarfaty C, Gribar JJ, Gottesman MM (2002) Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol 62:1-6
23. Krieger RI, Rosenheck LA, Schuester LL (1997) Adult and infant abamectin exposures following Avert 310 and pressurized gel crack and crevice treatment. Bull Environ Contam Toxicol 58:681-687
24. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Carlson EJ, Herskowitz I, Giacomini KM, Clark AG (2003) Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13:481-494
25. Kwei GY, Alvaro RF, Chen Q, Jenkins HJ, Hop CE, Keohane CA, Ly VT, Strauss JR, Wang RW, Wang Z, Pippert TR, Umbenhauer DR (1999) Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab Dispos 27:581-587
26. Lankas GR, Minsker DH, Robertson RT (1989) Effects of ivermectin on reproduction and neonatal toxicity in rats. Food Chem Toxicol 27:523-529
27. Lankas GR, Cartwright ME, Umbenhauer D (1997) P-Glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol Appl Pharmacol 143:357-365
28. Lankas GR, Wise LD, Cartwright ME, Pippert T, Umbenhauer DR (1998) Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol 12:457-463
29. Lanning CL, Wehner TA, Norton JA, Dunbar DM, Grosso LS (1997) Correlation of actual strawberry harvester exposure with that predicted from abamectin dislodgeable foliar residues. J Agric Food Chem 46:2340-2345
30. Lecoeur S, Videmann B, Mazallon M (2006) Effect of organophosphate pesticide diazinon on expression and activity of intestinal P-glycoprotein. M Toxicol Lett 161(3):200-209
31. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR (2006a) ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J. Advanced online publication
32. Leschziner G, Zabaneh D, Pirmohamed M, Owen A, Rogers J, Coffey AJ, Balding DJ, Bentley DB, Johnson MR (2006b) Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. Pharmacogenet Genomics 16:439-450
33. Leslie EM, Deeley RG, Cole SP (2005) Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216-237
34. Loo TW, Clarke DM (2005) Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J Membr Biol 206:173-185
35. Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75:13-33
36. Matsuoka Y, Okazaki M, Kitamura Y, Taniguchi T (1999) Developmental expression of P-glycoprotein (multidrug resistance gene product) in the rat brain. J Neurobiol 39:383-392
37. Mealey KL, Bentjen SA, Gay JM, Cantor GH (2001) Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 11:727-733
38. Morita N, Yasumori T, Nakayama K (2003) Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem Pharmacol 65:1843-1852
39. Moriya Y, Nakamura T, Horinouchi M, Sakaeda T, Tamura T, Aoyama N, Shirakawa T, Gotoh A, Fujimoto S, Matsuo M, Kasuga M, Okumura K (2002) Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol Pharm Bull 25:1356-1359
40. Mutoh K, Mitsuhashi J, Kimura Y, Tsukahara S, Ishikawa E, Sai K, Ozawa S, Sawada J, Ueda K, Katayama K, Sugimoto Y (2006) A T3587G germline mutation of the MDR1 gene encodes a nonfunctional P-glycoprotein. Mol Cancer Ther 5:877-884
41. Oselin K, Mrozikiewicz PM, Gaikovitch E, Pahkla R, Roots I (2003) Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: detection of a novel mutation G816A in the human MRP1 gene. Eur J Clin Pharmacol 59:347-350
42. Pacque MC, Dukuly Z, Greene BM, Munoz B, Keyvan-Larijani E, Williams PN, Taylor HR (1989) Community-based treatment of onchocerciasis with ivermectin: acceptability and early adverse reactions. Bull World Health Organ 67:721-730
43. Pippert TR, Umbenhauer DR (2001) The subpopulation of CF-1 mice deficient in P-glycoprotein contains a murine retroviral insertion in the mdr1a gene. J Biochem Mol Toxicol 15:83-89
44. Potocnik U, Ferkolj I, Glavac D, Dean M (2004) Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes Immun 5:530-539
45. Rodriguez Novoa S, Barreiro P, Rendon A, Barrios A, Corral A, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V (2006) Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C->T polymorphism at the multidrug resistance gene 1. Clin Infect Dis 42:291-295
46. Sakaeda T (2005) MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab Pharmacokinet 20:391-414
47. Schaefer M, Roots I, Gerloff T, (2006) In-vitro transport characteristics discriminate wild-type ABCB1(MDR1) from ALA893SER and ALA893THR polymorphisms. Pharmacogenet Genomics 16:855-861
48. Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, Schwab M (2001) Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 358:383-384
49. Schinkel AH, Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3-29
50. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP et al (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502
51. Schumacher U, Mollgard K (1997) The multidrug-resistance P-glycoprotein (Pgp, MDR1) is an early marker of blood-brain barrier development in the microvessels of the developing human brain. Histochem Cell Biol 108:179-182
52. Shilling RA, Venter H, Velamakanni S, Bapna A, Woebking B, Shahi S, van Veen HW (2006) New light on multidrug binding by an ATP-binding cassette transporter. Trends Pharmacol Sci 27(4):195-203
53. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, Wood NW, Sisodiya SM (2003) Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 348:1442-1448
54. Sills GJ, Mohanraj R, Butler E, McCrindle S, Collier L, Wilson EA, Brodie MJ (2005) Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 46:643-647
55. Skarke C, Jarrar M, Schmidt H, Kauert G, Langer M, Geisslinger G, Lotsch J (2003) Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 13:651-660
56. Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. (1999) Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest 104(10):1441-1447
57. Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W (2006) Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta 27:602-609
58. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219-234
59. Takane H, Kobayashi D, Hirota T, Kigawa J, Terakawa N, Otsubo K, Ieiri I (2004) Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. J Pharmacol Exp Ther 311:1179-1187
60. Takano A, Kusuhara H, Suhara T, Ieiri I, Morimoto T, Lee YJ, Maeda J, Ikoma Y, Ito H, Suzuki K, Sugiyama Y (2006) Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. J Nucl Med 47:1427-1433
61. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K (2001) Expression of P-glycoprotein in human placenta: relation to genetic. J Pharmacol Exp Ther 297:1137-1143
62. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738
63. Umbenhauer DR, Lankas GR, Pippert TR, Wise LD, Cartwright ME, Hall SJ, Beare CM (1997) Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol Appl Pharmacol 146:88-94
64. Urbatsch IL, Julien M, Carrier I, Rousseau ME, Cayrol R, Gros P (2000) Mutational analysis of conserved carboxylate residues in the nucleotide binding sites of P-glycoprotein. Biochemistry 39:14138-14149
65. Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P, Funck-Brentano C, Becquemont L (2003) Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 58:809-812
66. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W (2005) Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C > T affects mRNA stability. Pharmacogenet Genomics 15:693-704
67. Woodahl EL, Ho RJ (2004) The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab 5:11-19
68. Xing Q, Gao R, Li H, Feng G, Xu M, Duan S, Meng J, Zhang A, Qin S, He L (2006) Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 7(7):987-993
69. Yi SY, Hong KS, Lim HS, Chung JY, Oh DS, Kim JR, Jung HR, Cho JY, Yu KS, Jang IJ, Shin SG (2004) A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin Pharmacol Ther 76:418-427
70. Zimprich F, Sunder-Plassmann R, Stogmann E, Gleiss A, Dal-Bianco A, Zimprich A, Plumer S, Baumgartner C, Mannhalter C (2004) Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 63:1087-1089